Amicus Therapeutics Inc. (FOLD)
| Bid | 6.77 |
| Market Cap | 2.1B |
| Revenue (ttm) | 528.29M |
| Net Income (ttm) | -56.11M |
| EPS (ttm) | -0.18 |
| PE Ratio (ttm) | -37.94 |
| Forward PE | 20.67 |
| Analyst | Buy |
| Ask | 7.06 |
| Volume | 2,810,763 |
| Avg. Volume (20D) | 2,785,908 |
| Open | 6.64 |
| Previous Close | 6.70 |
| Day's Range | 6.63 - 6.88 |
| 52-Week Range | 6.20 - 12.65 |
| Beta | 0.79 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym...
Analyst Forecast
According to 9 analyst ratings, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 148.90% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...
1 month ago · seekingalpha.com
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call TranscriptAmicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - Pres...
